Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLKL | Q8NB16 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17263165 | 0.89 | MLKL (0.62) | MLKLRAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL12895233 | 0.81 | MLKL (0.54) | MLKLRAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL29488679 | 0.81 | ALDH1A1 (0.51) | MLKLRAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL19970851 | 0.80 | PPARG (0.48) | KDM4EALDH1A1HPGDGAAKMT2A | |
| SCHEMBL31695250 | 0.79 | CYP1A2 (0.51) | MLKLRAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL18689828 | 0.78 | MLKL (0.49) | MLKLSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL7033886 | 0.78 | ALDH1A1 (0.42) | MLKLRAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7409134 | 0.78 | F2 (0.55) | ALDH1A1IDO1 | |
| SCHEMBL392474 | 0.78 | ROCK2 (0.47) | MLKLRAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL19970799 | 0.77 | MAPK1 (0.41) | MLKLKDM4EALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-25 | — | — | US | disclosed |
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| EP-3512838-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | Centre National De La Recherche Scientifique (FR) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050771-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050771-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-22 | — | — | WO | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | FIP1L1, ZC3HAV1, MAVS | MLKL 1019/4885RAB9A 3131/4885SMN1; SMN2 491/4885 |
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | FIP1L1, ZC3HAV1, MAVS | MLKL 1019/4885RAB9A 3131/4885SMN1; SMN2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.